⚠️
RECORD CORRECTION — October 1, 2026
Electrolyte schedule corrected; BodyHealth electrolytes added. LMNT is taken only on Tuesdays and Saturdays (the 4x4 interval days), not daily as this protocol previously recorded. BodyHealth Perfect Amino Electrolytes (Lemon Lime), 1 scoop at the 11 AM meal, covers the other five days, so exactly one electrolyte powder is taken per day. Electrolyte-product sodium averages roughly 500 mg/day across the week (about 1,000 mg on LMNT days, about 300 mg on BodyHealth days). Nothing else in the protocol's logic changes; the Electrolyte & Hydration system card below has been updated.
Prior correction (Sep 16, 2026):
Berberine product and dose corrected. This protocol's berberine entry had been recorded as "Thorne Berberine-500" at 2 caps/day (implying 1000mg/day). The actual product on hand and in use is Thorne Berberine, 200mg/capsule (the current name for what Thorne formerly sold as "Berbercap"), taken 2 capsules/day = 400mg/day. No dose change is being made — this is a correction of the recorded product identity and mg-strength, not a change in what's actually being taken. Every mechanism described below (AMPK activation, PCSK9 downregulation) still applies at 400mg/day; the mechanistic logic in this report was never dose-specific and required no revision. See supplement-grading-report.html for the full correction detail and updated cost figures, and supplements_master.yaml for the corrected registry entry now driving every report that references berberine.
Also new this revision — Coronary Artery Calcium Score added. A CT calcium scan drawn Aug 22, 2026 put the Agatston score at 10 ("minimal" band) — the first direct structural measurement of arterial plaque burden this protocol has, distinct from the blood-based lipid risk factors tracked elsewhere. See the new box in the Cardiovascular & Lipid Management system card below.
Prior revision, September 14, 2026 — Triglyceride/berberine-washout hypothesis confirmed. A WellSpan lipid panel drawn Sep 14, 2026 — roughly 7 weeks into the on-cycle berberine period (resumed Jul 28, 2026) — put Triglycerides at 66 mg/dL, a series low, below the 85 mg/dL Mar 2026 reading and the prior 71 mg/dL Dec 2025 low. This confirms the Jul 2026 TG spike (144→153 mg/dL) was the berberine-washout artifact this report hypothesized, not a genuine new metabolic problem — closing the single highest-priority open item in the Redundancy & Gap Analysis below (formerly Gap 3). The Jul 27 NMR particle-level findings (LDL-P, small LDL, large HDL) were not re-measured at this draw — that recheck remains open, separately, pending a future NMR LipoProfile. Reflected below in: the Cardiovascular system card, the Protocol Overview priorities, Gap 3 → now "Resolved," and the Action Plan. Prior revisions (Sep 14 AM — Zinc Bisglycinate added; Aug 18 — BPC-157 switched to ProHealth; Aug 16 — Mitopure added) carry forward unchanged below.
Prior correction (Sep 16, 2026):
Berberine product and dose corrected. This protocol's berberine entry had been recorded as "Thorne Berberine-500" at 2 caps/day (implying 1000mg/day). The actual product on hand and in use is Thorne Berberine, 200mg/capsule (the current name for what Thorne formerly sold as "Berbercap"), taken 2 capsules/day = 400mg/day. No dose change is being made — this is a correction of the recorded product identity and mg-strength, not a change in what's actually being taken. Every mechanism described below (AMPK activation, PCSK9 downregulation) still applies at 400mg/day; the mechanistic logic in this report was never dose-specific and required no revision. See supplement-grading-report.html for the full correction detail and updated cost figures, and supplements_master.yaml for the corrected registry entry now driving every report that references berberine.
Also new this revision — Coronary Artery Calcium Score added. A CT calcium scan drawn Aug 22, 2026 put the Agatston score at 10 ("minimal" band) — the first direct structural measurement of arterial plaque burden this protocol has, distinct from the blood-based lipid risk factors tracked elsewhere. See the new box in the Cardiovascular & Lipid Management system card below.
Prior revision, September 14, 2026 — Triglyceride/berberine-washout hypothesis confirmed. A WellSpan lipid panel drawn Sep 14, 2026 — roughly 7 weeks into the on-cycle berberine period (resumed Jul 28, 2026) — put Triglycerides at 66 mg/dL, a series low, below the 85 mg/dL Mar 2026 reading and the prior 71 mg/dL Dec 2025 low. This confirms the Jul 2026 TG spike (144→153 mg/dL) was the berberine-washout artifact this report hypothesized, not a genuine new metabolic problem — closing the single highest-priority open item in the Redundancy & Gap Analysis below (formerly Gap 3). The Jul 27 NMR particle-level findings (LDL-P, small LDL, large HDL) were not re-measured at this draw — that recheck remains open, separately, pending a future NMR LipoProfile. Reflected below in: the Cardiovascular system card, the Protocol Overview priorities, Gap 3 → now "Resolved," and the Action Plan. Prior revisions (Sep 14 AM — Zinc Bisglycinate added; Aug 18 — BPC-157 switched to ProHealth; Aug 16 — Mitopure added) carry forward unchanged below.
🎯 Protocol Overview
This is not a collection of supplements — it's an integrated protocol. Every item was selected to address a specific physiological bottleneck identified through longitudinal bloodwork, genetic testing, and direct lab retesting — with one deliberate exception as of Aug 16, 2026 (Mitopure/Urolithin A, added proactively on trial evidence rather than a lab finding — see the Mitochondrial & Cellular Energy card below). Six therapeutic objectives, ranked below by where the data says the next bottleneck actually is — not by how long each objective has existed.
🧬
CURRENT PRIORITIES — AS OF SEP 16, 2026
1. Gut microbiome (Jun 2026 GI-MAP). Akkermansia muciniphila and F. prausnitzii confirmed undetectable; four supplements added in response, all at full dose since Jul 29. Verification pending the 6-month retest. Now the single highest-priority open item, with the triglyceride/berberine question below resolved.
2. Triglyceride/NMR particle cluster — TG confirmed resolved, NMR recheck still open. The Jul 2026 TG spike (144–153, both draws inside berberine's Jul 14–27 washout) is confirmed a washout artifact: the Sep 14, 2026 on-cycle retest came back at 66 mg/dL, a series low. The separate NMR particle findings from Jul 27 (LDL-P 1453, small LDL 298, large HDL 5861) were not re-measured at this draw and remain an open item pending a full NMR LipoProfile recheck — not urgent, since the TG driver behind them has now resolved.
3. Mitochondrial energy — new lever, not a bottleneck (Aug 16, 2026). Mitopure/Urolithin A joins CoQ10+PQQ as a third distinct lever (mitophagy clearance, not biogenesis or ETC substrate). This is a proactive longevity addition, the first in this protocol's history not tied to a lab or genetic finding — flagged here explicitly so it doesn't get read as correcting a deficiency it isn't.
2. Triglyceride/NMR particle cluster — TG confirmed resolved, NMR recheck still open. The Jul 2026 TG spike (144–153, both draws inside berberine's Jul 14–27 washout) is confirmed a washout artifact: the Sep 14, 2026 on-cycle retest came back at 66 mg/dL, a series low. The separate NMR particle findings from Jul 27 (LDL-P 1453, small LDL 298, large HDL 5861) were not re-measured at this draw and remain an open item pending a full NMR LipoProfile recheck — not urgent, since the TG driver behind them has now resolved.
3. Mitochondrial energy — new lever, not a bottleneck (Aug 16, 2026). Mitopure/Urolithin A joins CoQ10+PQQ as a third distinct lever (mitophagy clearance, not biogenesis or ETC substrate). This is a proactive longevity addition, the first in this protocol's history not tied to a lab or genetic finding — flagged here explicitly so it doesn't get read as correcting a deficiency it isn't.
23 active supplements map to 7 body systems (up from 22 with the Oct 1, 2026 BodyHealth Electrolytes addition, which sits in the Electrolyte & Hydration system alongside LMNT; before that, up from 21 with the Sep 14, 2026 standalone Zinc Bisglycinate addition; the Aug 16 Mitopure addition and the Aug 18 BPC-157 product switch are already folded into that prior count and don't change it further). Most supplements serve more than one system — this is intentional. Biological systems are interconnected, and the most effective interventions create cascading benefits across multiple pathways. The ranking above reflects current priority, not permanence: cardiovascular and metabolic remain the longest-running, most evidence-dense objectives in the stack — gut/microbiome is ranked #1 right now because it's the newest lab-driven finding still being actively resolved, not because it's more important in the abstract than the four-pathway lipid attack below it. Mitochondrial energy sits lower still, deliberately — it's the one addition here that isn't correcting anything.
🗺️ System-Level Mapping
Cardiovascular & Lipid Management
Revised Sep 16, 2026: CAC score (10, minimal) added as a structural corroboration — Sep 14 revision broke the LDL plateau AND resolved the triglyceride/berberine-washout question; NMR particle recheck remains the one open item
✅ NEW DATA POINT — Coronary Artery Calcium Score (Agatston): 10, Aug 22, 2026 — "minimal" band
A direct CT measure of calcified plaque burden in the coronary arteries — the single most predictive imaging test for future cardiac events, independent of cholesterol numbers entirely. A score of 10 sits just above the 0 = no calcified plaque floor, in the minimal band (0=none / 1–10 minimal / 11–100 mild / 101–400 moderate / >400 severe, Agatston risk bands).
This is a structural corroboration of the biomarker-level progress below, not a redundant data point: cholesterol and particle numbers describe risk factors circulating in blood; CAC describes what has actually accumulated in the artery wall over a lifetime. A minimal CAC score in a carrier of APOE e3/e4 with a multi-year history of elevated ApoB (peak 139, prior to the four-pathway lipid attack below) is a genuinely favorable finding — it says the risk factors this protocol has been correcting have not yet translated into meaningful structural disease.
Context, not a trend yet: this is a single baseline scan — there is no prior CAC draw to compare it against, so nothing here is a before/after story the way the lipid panels are. CAC is not an annual-recheck marker; imaging societies generally don't recommend rescoring sooner than 3–5 years absent a major change in risk profile, so the next natural checkpoint for this specific test is mid-decade, not the next quarterly panel. Logged manually here (and in bio.html's Cardiac Imaging group) since it doesn't flow through the Function Health blood-panel connector — it's a CT scan, not a blood draw.
This is a structural corroboration of the biomarker-level progress below, not a redundant data point: cholesterol and particle numbers describe risk factors circulating in blood; CAC describes what has actually accumulated in the artery wall over a lifetime. A minimal CAC score in a carrier of APOE e3/e4 with a multi-year history of elevated ApoB (peak 139, prior to the four-pathway lipid attack below) is a genuinely favorable finding — it says the risk factors this protocol has been correcting have not yet translated into meaningful structural disease.
Context, not a trend yet: this is a single baseline scan — there is no prior CAC draw to compare it against, so nothing here is a before/after story the way the lipid panels are. CAC is not an annual-recheck marker; imaging societies generally don't recommend rescoring sooner than 3–5 years absent a major change in risk profile, so the next natural checkpoint for this specific test is mid-decade, not the next quarterly panel. Logged manually here (and in bio.html's Cardiac Imaging group) since it doesn't flow through the Function Health blood-panel connector — it's a CT scan, not a blood draw.
✅ OBJECTIVE ACHIEVED — the four-pathway attack worked
LDL-C 125 → 108 mg/dL. ApoB 104 → 93 mg/dL (−33% from the 139 first measured Jan'25). Total cholesterol 198 → 190. Achieved without a statin, in a carrier of APOE e3/e4 — the genotype that made this plateau mechanistically stubborn in the first place. This is the clearest validation the protocol has produced.
Work remaining: ApoB 93 is still above the <80 optimal target. All four pathways stay at current dose — do not taper on one good panel.
Work remaining: ApoB 93 is still above the <80 optimal target. All four pathways stay at current dose — do not taper on one good panel.
✅ RESOLVED Sep 14, 2026 — the triglyceride/berberine-washout hypothesis was correct
Triglycerides: 71 (Dec'25) → 85 (Mar'26) → 144–153 (Jul'26) → 66 (Sep'26). The Jul 2026 rise happened on two draws taken during berberine's Jul 14–27 washout (day 7 and day 14). The gating action — an on-cycle retest — happened Sep 14, 2026, roughly 7 weeks back on berberine: Triglycerides came back at 66 mg/dL, the lowest value in the entire series, below both the 85 Mar'26 baseline and the 71 Dec'25 prior low.
This confirms the mechanism this report proposed in Aug 2026: berberine's AMPK activation suppresses hepatic lipogenesis and VLDL output, and withdrawing it during the scheduled washout raised TG output exactly as predicted — not a genuine new metabolic problem. The triglyceride-level concern is closed.
What's still open, honestly: the Sep 14 draw was a standard lipid panel (Friedewald-calculated LDL-C), not an NMR LipoProfile — the Jul 27 particle-level findings (LDL-P 1453 nmol/L, small LDL 298 nmol/L, large HDL 5861 nmol/L) were not re-measured. Those findings tracked with elevated TG mechanistically (see CETP exchange, below), so a TG return to a series-low value is a strong signal they've also normalized — but that is now an inference, not a confirmed re-measurement. A full NMR recheck remains a separate, lower-urgency open item.
The Pattern A trap: the Jul 27 panel labeled you Pattern A — the favorable classification — at the same draw the particle sub-markers were flagged. That was not a contradiction: Pattern A is a coarse peak-particle-diameter call (~205Å cutoff); the flagged sub-markers are individual reference-range comparisons. Different scoring systems answering different questions.
Why these were one problem, not four: triglyceride-rich VLDL exchanges TG for cholesteryl ester with LDL and HDL via CETP. Hepatic lipase then strips the TG-enriched particles down — LDL shrinks into a greater number of small dense particles, and large HDL is catabolized and depleted. Elevated TG was the root node. With triglycerides back to a series low, the mechanistic driver behind the particle findings is gone — consistent with (though not proof of) those findings having normalized too.
This confirms the mechanism this report proposed in Aug 2026: berberine's AMPK activation suppresses hepatic lipogenesis and VLDL output, and withdrawing it during the scheduled washout raised TG output exactly as predicted — not a genuine new metabolic problem. The triglyceride-level concern is closed.
What's still open, honestly: the Sep 14 draw was a standard lipid panel (Friedewald-calculated LDL-C), not an NMR LipoProfile — the Jul 27 particle-level findings (LDL-P 1453 nmol/L, small LDL 298 nmol/L, large HDL 5861 nmol/L) were not re-measured. Those findings tracked with elevated TG mechanistically (see CETP exchange, below), so a TG return to a series-low value is a strong signal they've also normalized — but that is now an inference, not a confirmed re-measurement. A full NMR recheck remains a separate, lower-urgency open item.
The Pattern A trap: the Jul 27 panel labeled you Pattern A — the favorable classification — at the same draw the particle sub-markers were flagged. That was not a contradiction: Pattern A is a coarse peak-particle-diameter call (~205Å cutoff); the flagged sub-markers are individual reference-range comparisons. Different scoring systems answering different questions.
Why these were one problem, not four: triglyceride-rich VLDL exchanges TG for cholesteryl ester with LDL and HDL via CETP. Hepatic lipase then strips the TG-enriched particles down — LDL shrinks into a greater number of small dense particles, and large HDL is catabolized and depleted. Elevated TG was the root node. With triglycerides back to a series low, the mechanistic driver behind the particle findings is gone — consistent with (though not proof of) those findings having normalized too.
Why this system still needs intervention: the atherogenic particle burden was, as of the last direct measurement, better characterized than it had ever been and not yet at target — and while the TG driver behind it is now resolved, the particle numbers themselves haven't been re-checked. Conventional medicine would prescribe a statin. This protocol continues to attack lipids through four independent non-pharmaceutical mechanisms, with the emphasis staying on the synthesis/clearance pathways that delivered the LDL/ApoB win, while a future NMR recheck (not urgent) will confirm the particle-level picture has followed triglycerides back down.
Assigned Supplements
🔴 Red Yeast Rice
Mechanism: Contains monacolin K, a natural HMG-CoA reductase inhibitor — the same mechanism as statins, but at a lower dose with fewer side effects.
Pathway: LDL Synthesis Reduction
🫀 Berberine
Mechanism: Downregulates PCSK9, which upregulates LDL receptors on hepatocytes — your liver pulls more LDL out of circulation. Thorne Berberine, 200mg/capsule, 2 caps/day (400mg/day) — corrected Sep 16, 2026 from a prior mis-record as "Berberine-500."
Pathway: LDL Clearance Enhancement
🐟 Super EPA Pro
Mechanism: EPA/DHA reduce hepatic VLDL secretion and accelerate triglyceride clearance. Also produce anti-inflammatory resolvins and protectins. Take with the fattiest meal — this is an ethyl ester product, not rTG.
Pathway: Triglyceride/VLDL Clearance + Anti-Inflammatory
🌾 FiberMend
Mechanism: Soluble fiber binds bile acids in the gut, forcing the liver to pull cholesterol from blood to synthesize replacement bile. Also produces SCFAs that suppress hepatic cholesterol synthesis.
Pathway: Bile Acid Sequestration + SCFA Signaling
Multi-Vector Lipid Attack — 4 Independent Pathways
Red Yeast Rice→HMG-CoA Reductase ↓→LDL Synthesis ↓
Berberine→PCSK9 ↓ → LDLR ↑→LDL Clearance ↑
Super EPA Pro→VLDL Secretion ↓→Triglycerides ↓ / Inflammation ↓
FiberMend→Bile Acid Binding→Cholesterol Excretion ↑
⟶Net Result: LDL ↓ / ApoB ↓ / TG ↓ / hs-CRP ↓
This is the same multi-vector strategy used in advanced lipidology — hitting synthesis, clearance, excretion, and inflammation simultaneously. The redundancy is intentional: if one pathway underperforms, the others compensate.
Metabolic & Glucose Control
Revised objective (Aug 2026): target achieved — mode shifts from correction to maintenance
✅ OBJECTIVE ACHIEVED — and the "regression" was never real
Fasting glucose 104 → 87 mg/dL. Insulin 8.4 → 6.0 µIU/mL. A1c holding at 5.1. All three are the best readings in the entire series. Insulin is down 87% from the 44.5 baseline.
The ~104 flag was a point-in-time outlier, not a trend. A 15-day Stelo CGM (Jul 12–27, 4,269 readings) put mean glucose at 89.7 mg/dL with 97.6% time-in-range and 0% above 180.
Mechanistic caveat worth keeping: the 23andMe findings (TCF7L2, SLC30A8) point to insulin secretion rather than insulin resistance as this system's genetic vulnerability. Maintenance is still warranted — the objective changed, it didn't disappear.
The ~104 flag was a point-in-time outlier, not a trend. A 15-day Stelo CGM (Jul 12–27, 4,269 readings) put mean glucose at 89.7 mg/dL with 97.6% time-in-range and 0% above 180.
Mechanistic caveat worth keeping: the 23andMe findings (TCF7L2, SLC30A8) point to insulin secretion rather than insulin resistance as this system's genetic vulnerability. Maintenance is still warranted — the objective changed, it didn't disappear.
🔬 Architectural consequence — berberine's role was reassigned
Berberine's Jul 14–27 cycling reset overlapped the CGM window, producing an accidental within-subject experiment. Daily mean glucose fell throughout the washout: ~98 → ~91 → ~85 → ~82. Control improved without berberine.
That doesn't say berberine is useless — it says its value has moved to the lipid side (re-slotted in the cardiovascular card above), and the Sep 14, 2026 on-cycle triglyceride retest (66 mg/dL, series low) confirms that reassignment was correct. The likelier current driver of glycemic improvement is the Phase 4 gut stack — 15 days of correlation, not proof, but the best natural experiment this protocol has generated.
That doesn't say berberine is useless — it says its value has moved to the lipid side (re-slotted in the cardiovascular card above), and the Sep 14, 2026 on-cycle triglyceride retest (66 mg/dL, series low) confirms that reassignment was correct. The likelier current driver of glycemic improvement is the Phase 4 gut stack — 15 days of correlation, not proof, but the best natural experiment this protocol has generated.
Why this system still needs intervention: maintenance, not correction. Pre-diabetes is reversed and the numbers are optimal; the job now is holding a setpoint that took two years to move, against a genetic background of reduced secretory reserve.
🫀 Berberine
Mechanism: AMPK activator. Increases glucose uptake in skeletal muscle independently of insulin. Thorne Berberine, 200mg/capsule, 2 caps/day (400mg/day).
Dual-system: Lipid + Glucose
💊 Basic Nutrients 2/Day
Mechanism: 400 mcg chromium picolinate enhances insulin receptor phosphorylation.
Insulin Receptor Sensitization
💪 Creatine
Mechanism: Increases GLUT4 translocation to muscle cell membranes.
Muscle Glucose Uptake
Glucose Control Stack — 3 Convergent Mechanisms
Berberine→AMPK ↑→Glucose Uptake ↑ (insulin-independent)
Chromium (in Basic Nutrients)→Insulin Receptor ↑→Glucose Disposal ↑ (insulin-dependent)
Creatine→GLUT4 Translocation ↑→Muscle Glucose Sink ↑
⟶Net Result: Fasting Glucose ↓ / A1C Maintenance / Insulin Sensitivity ↑
Berberine works without insulin (AMPK pathway), chromium works with insulin (receptor sensitization), and creatine increases the tissue capacity to absorb glucose. Three different doors into the same room.
Methylation & Genetic Support
Primary objective: compensate for MTHFR and MTRR mutations with correct nutrient forms
Why this system needs intervention: MTHFR A1298C heterozygous means ~30% reduced capacity to convert folic acid → 5-MTHF. MTRR A66G heterozygous means impaired methionine synthase reductase — the enzyme that reactivates B12 for methionine recycling. Without support, homocysteine accumulates, DNA repair is impaired, and neurotransmitter production is compromised.
🧬 Methyl-Guard Plus
The primary methylation engine. 5-MTHF (1,000 mcg) bypasses the MTHFR bottleneck entirely. Methylcobalamin B12 (1,000 mcg) provides the active form the MTRR mutation can actually use. Riboflavin-5'-phosphate (25 mg) serves as the FAD cofactor MTHFR needs. TMG/betaine (1,500 mg) provides an alternative homocysteine → methionine pathway (BHMT) that doesn't depend on folate at all.
Complete methylation cycle coverage
💊 Basic Nutrients 2/Day
Methylation backup layer. Methylcobalamin (not cyanocobalamin) and methylfolate (not folic acid) ensure baseline methylation support even if Methyl-Guard Plus is missed.
Redundant methylation safety net
Methylation Cycle — Dual Pathway Coverage
5-MTHF (Methyl-Guard)→Methionine Synthase→Homocysteine → Methionine→SAMe Production ↑
Methylcobalamin (Methyl-Guard + Basic Nutrients)→MTR/MTRR Enzyme Support→B12 Recycling ↑
TMG/Betaine (Methyl-Guard)→BHMT Enzyme (alternate route)→Homocysteine → Methionine (backup)
⟶Net Result: Homocysteine ↓ / DNA Methylation ↑ / Neurotransmitter Production ↑
Neurological & COMT Phenotype Management
Primary objective: manage catecholamine pooling from COMT homozygous status
Why this system needs intervention: COMT G472A homozygous positive means the catechol-O-methyltransferase enzyme functions at only 0-10% of normal capacity. Dopamine, norepinephrine, and epinephrine persist in synapses far longer than intended — sharper focus under low stress, but vulnerability to anxiety, sleep disruption, and overstimulation under moderate-to-high stress. The strategy isn't to fix COMT — it's to provide alternative calming pathways that bypass the catecholamine bottleneck entirely.
🧠 NeuroCalm
Multi-vector calming complex. PharmaGABA for immediate alpha-wave promotion. L-theanine for sustained alpha activity without sedation. 5-HTP + P5P for serotonin building. Taurine for tonic inhibition. Phosphatidylserine for HPA axis cortisol blunting.
5 calming vectors in one formula
🧲 Magnesium Glycinate
Dual COMT role. Magnesium is the cofactor COMT requires; glycinate form activates GABA receptors directly. Evening dosing supports sleep architecture.
COMT cofactor + GABA agonist
🍄 Lion's Mane
Neuroplasticity via NGF. Stimulates nerve growth factor production — safe for COMT phenotype because it doesn't inhibit catecholamine clearance or increase catecholamine production.
Neuroplasticity (COMT-safe)
COMT Bypass Strategy — Alternative Calming Pathways
COMT Dysfunction (0-10%)→Catecholamine Pooling→Overstimulation Risk
↓ Protocol Response (bypass, don't fix):
PharmaGABA + Taurine→Direct GABA-ergic inhibition→Acute calming (minutes)
L-Theanine→Alpha wave promotion→Calm focus without sedation
5-HTP + P5P→Serotonin synthesis ↑→Mood floor elevation (weeks)
Phosphatidylserine→Cortisol blunting (HPA axis)→Stress resilience (weeks)
Magnesium Glycinate→COMT cofactor + GABA agonist→Enzyme support + sleep
Gut Architecture & Microbiome
Primary objective: maintain barrier integrity and microbiome diversity post-protocol
Why this system needs intervention: years of metabolic dysfunction, inflammation, and potential intestinal permeability required a 3-phase gut repair protocol (Clear → Repair → Repopulate). That protocol succeeded on its own terms — the June 2026 GI-MAP retest shows the pathogenic EPEC/EHEC E. coli from the Oct 2025 test fully cleared, calprotectin at 0, and pancreatic/digestive function excellent. But the retest also surfaced a new finding: Akkermansia muciniphila and Faecalibacterium prausnitzii are both undetectable — the two most metabolically important keystone species in the gut. This reframes the gut system from "maintenance" to Phase 4 — Optimize Keystone Species: selectively feed and restore what's missing rather than run another antimicrobial round against the mild secondary flags (Pseudomonas, Streptococcus, Candida, low-virulence H. pylori) that came with it.
Physician-confirmed, Jul 2026:
Dr. Nguyen independently reviewed this same GI-MAP and reached the same conclusion — no eradication needed, focus on beneficial bacteria — and specifically named Pendulum Akkermansia, PHGG, and Tri-Butyrin Supreme as the right additions. He also confirmed the rest of this stack "looks great" and won't interfere.
🦠 Seed DS-01
24-strain synbiotic. ViaCap® technology delivers strains past stomach acid.
Microbial diversity + barrier maintenance
🌾 FiberMend
Prebiotic fiber. Feeds beneficial bacteria; produces SCFAs. Also serves lipid management (bile acid binding).
Dual-system: Gut + Lipid
🩹 Pure BPC-157 (ProHealth)
Mucosal repair peptide. Promotes angiogenesis, supports tight junction protein expression. Cycling 4 on/2 off. Switched from Apeiron Elements BPC-157 Prime w/CurcuPrime Aug 18, 2026 — same mechanism and cycling schedule, single-ingredient product going forward.
Structural repair + tight junctions
🧬 Phase 4 Additions — Keystone Species Repletion (Jul 2026, all at full dose since Jul 29)
🦠 Akkermansia 500 PRO
Direct strain repletion. Live Akkermansia muciniphila, restoring the species confirmed undetectable. Confirmed-zero repletion, not a general-population guess.
Gut + Metabolic dual-system
🌾 Sunfiber (PHGG)
F. prausnitzii substrate. No standalone F. prausnitzii probiotic exists (obligate anaerobe) — the only lever is feeding it. Full 7g/day dose reached Jul 26.
Gut — targeted prebiotic
🧈 Tri-Butyrin Supreme
Butyrate bridge. Supplies the downstream metabolite F. prausnitzii would normally produce. 4-month course, reassess.
Gut — postbiotic bridge
🧪 MegaPre (capsules)
Dual-species precision prebiotic. Multi-fiber blend feeding Akkermansia, F. prausnitzii, and Bifidobacterium simultaneously. Full 6-capsule dose since Jul 29.
Gut — broad-spectrum prebiotic
Gut Architecture Stack — 4-Layer (Repair → Colonize → Feed → Restore Keystones)
BPC-157→Mucosal repair + tight junctions→Structural integrity (Layer 1)
Seed DS-01→Probiotic colonization→Microbial diversity (Layer 2)
FiberMend + Sunfiber + MegaPre→Prebiotic SCFA production→Microbe feeding + immune signaling (Layer 3)
Akkermansia 500 PRO + Tri-Butyrin Supreme→Direct strain + postbiotic repletion→Keystone species restoration (Layer 4)
⟶Net Result: Barrier Integrity ↑ / SCFA Production ↑ / Inflammation ↓ / Akkermansia + F. prausnitzii restored
Mitochondrial & Cellular Energy
Biogenesis, mitophagy, ATP substrate & recycling — the "power plant" layer underneath every other system
Why this system needs intervention. Mitochondrial density and function decline with age independent of any single lab marker — there is no standard blood test that flags "your mitochondria are getting worse," which is exactly why this system was under-addressed for years relative to lipids or glucose. The functional consequence shows up indirectly: training capacity, recovery speed, and the subjective sense of cellular "fuel" all trace back to how many healthy mitochondria a cell has and how efficiently they turn substrate into ATP. This system is addressed proactively, not reactively — the goal is to extend the runway before decline becomes measurable rather than to correct a flagged deficiency.
🆕 MITOPURE (UROLITHIN A) 1000MG — Added Aug 16, 2026
Primary mechanism — mitophagy. Urolithin A triggers the clearance of damaged, dysfunctional mitochondria (mitophagy) via a pathway distinct from both PQQ and CoQ10. Ryu et al., Nature Medicine 2016, first demonstrated this in muscle tissue — it doesn't build new mitochondria or improve output of existing ones, it removes the ones dragging the average down, which is the mechanistic gap neither PQQ nor CoQ10 fills.
Secondary — muscle strength & endurance. A 2022 randomized trial in Cell Reports Medicine showed measurable gains in muscle strength and endurance in middle-aged and older adults over a 4-month course at doses in the 500–1000mg range, without a resistance-training intervention layered on top — relevant given the standing priority of preserving muscle mass through any future fat-loss phase.
Tertiary / exploratory. A 2025 randomized trial examining immune-aging markers reported favorable shifts with Urolithin A supplementation in older adults; this is early-stage evidence and treated here as a plausible bonus, not a primary rationale.
Dose rationale. 1000mg/day matches the dose used in both the Ryu et al. mechanistic work and the Cell Reports Medicine strength trial — the goal is to replicate what was actually studied rather than under-dose against a Amazon/Fullscript label default.
Timing. 11 AM, taken with the fattiest portion of the day's largest meal — Urolithin A is fat-soluble and absorption benefits meaningfully from co-ingested dietary fat, consistent with the sourcing rationale already on file in claude/Mitopure_Buying_Guide_Aug2026.html and claude/Mitopure_Urolithin_A_Deep_Dive_Aug2026.html (including the 2023 counterfeit-product warning that drove the Fullscript/Timeline-direct purchasing decision over third-party marketplace listings).
Secondary — muscle strength & endurance. A 2022 randomized trial in Cell Reports Medicine showed measurable gains in muscle strength and endurance in middle-aged and older adults over a 4-month course at doses in the 500–1000mg range, without a resistance-training intervention layered on top — relevant given the standing priority of preserving muscle mass through any future fat-loss phase.
Tertiary / exploratory. A 2025 randomized trial examining immune-aging markers reported favorable shifts with Urolithin A supplementation in older adults; this is early-stage evidence and treated here as a plausible bonus, not a primary rationale.
Dose rationale. 1000mg/day matches the dose used in both the Ryu et al. mechanistic work and the Cell Reports Medicine strength trial — the goal is to replicate what was actually studied rather than under-dose against a Amazon/Fullscript label default.
Timing. 11 AM, taken with the fattiest portion of the day's largest meal — Urolithin A is fat-soluble and absorption benefits meaningfully from co-ingested dietary fat, consistent with the sourcing rationale already on file in claude/Mitopure_Buying_Guide_Aug2026.html and claude/Mitopure_Urolithin_A_Deep_Dive_Aug2026.html (including the 2023 counterfeit-product warning that drove the Fullscript/Timeline-direct purchasing decision over third-party marketplace listings).
Life Extension CoQ10 + PQQ
CoQ10 (ubiquinol form) is the direct electron-transport-chain substrate — it's consumed in the process of making ATP, and endogenous synthesis declines with age. PQQ is the biogenesis signal — it upregulates PGC-1α, the master switch that tells cells to build new mitochondria rather than just run the existing ones better. Between the two, this pair covers substrate supply and new-mitochondria signaling, but neither addresses clearance of damaged mitochondria — the gap Mitopure now fills.
Creatine Monohydrate
Buffers the phosphocreatine system for rapid ATP recycling during high-intensity effort, independent of mitochondrial output — this is the "fast" energy layer that complements the "slow," mitochondria-dependent layer the other three supplements in this system address. Also carries a secondary methylation-support role (see Methylation & Genetic Support) since creatine synthesis is itself a methylation-demanding pathway, and dual roles like this reduce net methyl-donor burden elsewhere in the stack.
Mitochondrial Energy Stack — 4-Node Pathway (Clear → Build → Fuel → Recycle)
Mitopure (Urolithin A)→Mitophagy — clears damaged mitochondria→Cleaner mitochondrial pool
PQQ→PGC-1α signaling — biogenesis→New mitochondria built
CoQ10 (ubiquinol)→Electron transport chain substrate→ATP output per mitochondrion
Creatine→Phosphocreatine buffering→Rapid ATP recycling (non-mitochondrial)
⟶Net Result: Fewer damaged mitochondria / More new mitochondria / Higher ATP output per mitochondrion / Faster ATP recycling under load
Immune, Hormonal & Structural
Vitamin D receptor signaling, calcium routing, and the D3/K2 pairing that makes both work correctly
Vitamin D3 + K2 (MK-7). D3 is foundational to immune modulation (upregulates regulatory T-cell activity), bone mineral density, and — relevant given the COMT/methylation genetics — has downstream interaction with hormone metabolism pathways. Supplementing D3 alone, without K2, raises a legitimate concern: D3 increases calcium absorption from the gut, and without K2 activating the proteins that direct that calcium into bone rather than soft tissue (arterial walls in particular), the net effect on cardiovascular risk is ambiguous at best. K2 (MK-7 form specifically, for its longer half-life versus MK-4) activates matrix Gla-protein and osteocalcin, routing calcium into bone and teeth and away from arteries. Given the existing cardiovascular risk profile this stack is already managing (elevated ApoB/particle count history), pairing D3 with K2 rather than taking D3 in isolation is treated as non-negotiable — see the Critical Pairing note in Synergy & Sequencing below.
🔩 Zinc Bisglycinate 15mg
Thorne Zinc Bisglycinate 15mg, 1 capsule/day with the 11 AM meal — added Sep 14, 2026 (ordered Sep 10). Standalone repletion, separate from the trace amount in Basic Nutrients 2/Day. Zinc is a required cofactor for T4→T3 thyroid conversion and for over 300 other enzymatic reactions, and was tracked as a slow-moving trend marker — in-range but declining (see Gap 4 in Redundancy & Gap Analysis) — before this addition closed the gap. Dosed with copper monitoring in mind, since chronic zinc repletion without copper can drive a secondary copper deficiency over long courses. Bisglycinate form chosen for gentler GI tolerance and reliable absorption relative to oxide forms.
Electrolyte & Hydration
Sodium/potassium/magnesium balance under training load and a lower-processed-food, lower-sodium baseline diet
Schedule corrected Oct 1, 2026 — two products, alternating days
LMNT is taken only on Tuesdays and Saturdays (the 4x4 days). BodyHealth Perfect Amino Electrolytes (Lemon Lime), 1 scoop at 11 AM, covers the other five days. One electrolyte powder per day, never both. Weekly average from the two products: about 500 mg sodium, ~236 mg potassium and ~53 mg magnesium per day (dietary intake not included). BodyHealth also carries ~2 mg zinc per scoop, which is counted in the zinc total on those days (~32 mg, under the 40 mg adult upper limit). Per-product label figures are from retailer listings and are worth verifying against the containers.
LMNT. A whole-foods, nutrient-dense eating pattern is, somewhat counterintuitively, often lower in sodium than the standard diet it replaces (most dietary sodium in a typical intake comes from processed and restaurant food, not the salt shaker) — combined with training volume, this creates a real electrolyte-replacement need rather than a marketing one. LMNT's ratio (high sodium, moderate potassium, modest magnesium) is designed around training/sweat losses rather than general hydration, and it's unsweetened-with-stevia rather than built on a sugar base, consistent with the ultra-processed-minimization principle. This supplement sits outside the lab-driven and genetics-driven logic that governs most of the rest of the stack — it's a training-support tool, included here for completeness of the full protocol picture rather than because a biomarker flagged it.
🗺️ Cross-System Supplement Map
| Supplement | Cardio | Metabolic | Methylation | Neuro | Gut | Mito/Energy | Immune/Struct |
|---|---|---|---|---|---|---|---|
| Red Yeast Rice | ● | ||||||
| Berberine | ● | ● | ○ | ||||
| Super EPA Pro | ● | ○ | |||||
| FiberMend | ○ | ○ | ● | ||||
| Basic Nutrients 2/Day | ● | ● | ○ | ||||
| Creatine | ○ | ○ | ● | ||||
| Methyl-Guard Plus | ● | ● | |||||
| NeuroCalm | ● | ||||||
| Magnesium Glycinate | ○ | ○ | ● | ||||
| Lion's Mane | ● | ||||||
| Seed DS-01 | ● | ○ | |||||
| 🔄 Pure BPC-157 (ProHealth) | ● | ||||||
| Akkermansia 500 PRO | ○ | ○ | ● | ||||
| Sunfiber (PHGG) | ● | ||||||
| Tri-Butyrin Supreme | ● | ||||||
| MegaPre | ● | ||||||
| CoQ10 + PQQ | ○ | ● | |||||
| 🆕 Mitopure (Urolithin A) | ● | ||||||
| Vitamin D3 + K2 | ○ | ● | |||||
| 🆕 Zinc Bisglycinate 15mg | ○ | ● | |||||
| LMNT (Tue/Sat) | ● | ||||||
| 🆕 BodyHealth Electrolytes (other days) | ● | ||||||
| System Coverage | 4 primary + 3 supporting | 3 primary + 3 supporting | 2 primary | 4 primary + 1 supporting | 7 primary + 2 supporting | 3 primary (was 2 pre-Aug16) | 5 primary + 2 supporting |
● = primary role in this system ○ = secondary/supporting role
🧬 Genetic Alignment
Every supplement in this stack is cross-checked against all four genetic findings before it's added — not just the ones it was chosen for. A supplement that's neutral or beneficial for one variant but works against another wouldn't make it in.
COMT G472A — Homozygous (slow dopamine/catecholamine clearance)
| Supplement | Interaction | Status |
|---|---|---|
| NeuroCalm (incl. L-Theanine) | Calming without stimulating catecholamine synthesis; avoids the overstimulation risk slow-COMT carriers get from stimulant-style "focus" stacks. | Beneficial |
| Magnesium Glycinate | Cofactor support for catecholamine breakdown enzymes broadly; calming, non-stimulating delivery form. | Beneficial |
| Methyl-Guard Plus | Methylated B-vitamins support COMT's methylation-dependent clearance step directly — this is a targeted, not incidental, benefit. | Essential |
| Basic Nutrients 2/Day | Broad-spectrum methylated multivitamin backing the same clearance pathway. | Essential |
| Lion's Mane | Nerve growth factor support; no interaction with catecholamine metabolism. | Neutral |
| Creatine | No direct COMT interaction; secondary methylation-demand note applies more to MTHFR/MTRR below. | Neutral |
| Super EPA Pro | Anti-inflammatory, no catecholamine pathway interaction. | Neutral |
| 🆕 Mitopure (Urolithin A) | Mitophagy mechanism is independent of catecholamine metabolism — checked specifically because dopaminergic neurons are unusually mitochondria-dense, but no COMT-pathway interaction identified. | Neutral |
| 🔄 Pure BPC-157 (ProHealth) | Mucosal-repair/growth-factor mechanism (EGF/VEGF/FGF, angiogenesis) is independent of catecholamine metabolism — no COMT-pathway interaction identified, consistent with the discontinued Apeiron product this replaces. | Neutral |
| 🆕 Zinc Bisglycinate 15mg | Zinc is a cofactor in numerous enzymatic reactions but has no established interaction with COMT-mediated catecholamine clearance. | Neutral |
| All other supplements | No identified interaction with COMT-mediated clearance. | Neutral |
MTHFR A1298C — Heterozygous (reduced folate methylation efficiency)
| Supplement | Interaction | Status |
|---|---|---|
| Methyl-Guard Plus | Delivers pre-methylated folate (5-MTHF) and B12, bypassing the reduced-efficiency conversion step entirely rather than asking the enzyme to work harder. | Essential |
| Basic Nutrients 2/Day | Methylated-form multivitamin backbone; avoids folic acid, which can accumulate unconverted in reduced-MTHFR carriers. | Essential |
| Creatine | Creatine synthesis itself consumes methyl groups (via SAMe) — supplementing creatine directly reduces the endogenous methylation burden this variant already handles less efficiently. | Beneficial |
| All other supplements | No folate/methylation-cycle interaction identified; no folic-acid-fortified products in the stack. | Neutral |
| 🆕 Mitopure (Urolithin A) | Not methylated or methylation-dependent in its metabolism (gut-bacteria-mediated conversion from ellagitannins); confirmed no folate-cycle interaction. | Neutral |
| 🔄 Pure BPC-157 (ProHealth) | Not folate- or methylation-cycle dependent in its repair mechanism; confirmed no MTHFR-pathway interaction, same as the outgoing Apeiron product. | Neutral |
| 🆕 Zinc Bisglycinate 15mg | Not folate- or methylation-cycle dependent; no MTHFR-pathway interaction identified. | Neutral |
MTRR A66G — Heterozygous (reduced B12 recycling)
| Supplement | Interaction | Status |
|---|---|---|
| Methyl-Guard Plus | Methylcobalamin (active B12 form) plus folate; covers the B12-recycling shortfall from three separate delivery angles across the stack (see B12 Delivery redundancy below). | Essential |
| Basic Nutrients 2/Day | Second methylcobalamin source at multivitamin-level dose. | Beneficial |
| Seed DS-01 | Some probiotic strains support endogenous B12 synthesis in the gut as a tertiary, minor contribution. | Beneficial |
| All other supplements | No B12-cycle interaction identified. | Neutral |
| 🆕 Mitopure (Urolithin A) | No B12/cobalamin pathway interaction. | Neutral |
| 🔄 Pure BPC-157 (ProHealth) | No B12/cobalamin pathway interaction; receptor/growth-factor-mediated mechanism unrelated to methylation. | Neutral |
| 🆕 Zinc Bisglycinate 15mg | No B12/cobalamin pathway interaction. | Neutral |
APOE e3/e4
One e4 allele raises long-term cardiovascular and neurodegenerative risk relative to e3/e3, and is the background rationale — alongside the labs themselves — for how aggressively the cardiovascular system above is being managed, and for the standing preference to keep saturated fat intake moderate rather than embrace it freely under a general "fat is fine" framing. Super EPA Pro and the red yeast rice/berberine/FiberMend lipid stack are all, in part, APOE-e4-informed choices. Mitopure, the Aug 18 BPC-157 product switch, and the Sep 14 Zinc Bisglycinate addition have no established APOE interaction in the literature reviewed; nothing here changes that reasoning.
Genetic Alignment Score: 22/22 Compatible (as of the Sep 16, 2026 revision; BodyHealth Electrolytes, added Oct 1, shows no ingredient with a known interaction with the four variants on its retailer-listed label, but that is a provisional read and not yet a full individual review). Every supplement in the current stack, including the Sep 14, 2026 Zinc Bisglycinate addition, the Aug 16 Mitopure addition, and the Aug 18 BPC-157 product switch (Apeiron → ProHealth Longevity), has been checked against all four genetic findings (COMT, MTHFR, MTRR, APOE) with no identified conflicts. No supplement in the protocol works against a genetic vulnerability it wasn't specifically chosen to address.
🔗 Synergy & Sequencing
1. Lipid Synergy Chain
Red Yeast Rice → lowers hepatic cholesterol synthesis (statin-like HMG-CoA reductase inhibition, natural monacolin K) → Berberine → AMPK activation, independent LDL-receptor upregulation → Super EPA Pro → triglyceride/VLDL reduction via hepatic lipogenesis suppression → FiberMend → binds bile acids, forces cholesterol recycling from blood. Four independent mechanisms converging on one outcome — this is why LDL/ApoB moved as far as it did without a statin.
2. Metabolic Synergy Chain
Berberine → AMPK activation improves insulin sensitivity → Basic Nutrients (chromium) → supports insulin receptor signaling → Creatine → improves glucose disposal into muscle independent of insulin via GLUT4 translocation. Three mechanisms, one of which (creatine) works through a completely insulin-independent pathway — this is part of why glucose/insulin/A1c all normalized together.
3. Methylation → Neurological Synergy
Methyl-Guard Plus → supplies methylated folate + B12, restoring efficient COMT-substrate clearance → reduces catecholamine buildup at the source → NeuroCalm + Magnesium Glycinate → manage what buildup remains downstream. Methylation support and calming support are sequential, not redundant — one reduces the problem, the other manages what's left.
4. NeuroCalm Internal Synergy
L-Theanine (alpha-wave promotion, non-sedating) → GABA (direct inhibitory neurotransmitter support) → Ashwagandha (cortisol modulation) combine inside a single formula to hit three distinct calming mechanisms simultaneously rather than relying on any one pathway to carry the full effect — relevant given slow-COMT carriers need broader downstream support, not just more of one lever.
5. Evening Calming Synergy
Magnesium Glycinate (evening dose) → NeuroCalm (evening dose) → both timed for the pre-sleep window, compounding calming effect right when slow-COMT catecholamine buildup is otherwise most likely to interfere with sleep onset.
6. Gut Ecosystem Synergy
BPC-157 (repairs the physical barrier) → Seed DS-01 (recolonizes with diverse probiotic species) → FiberMend + Sunfiber + MegaPre (feed what's been recolonized) → Akkermansia 500 PRO + Tri-Butyrin Supreme (restore/bridge the two keystone species directly). Repair, then colonize, then feed, then restore keystones — sequenced in the order the gut ecosystem actually rebuilds, not in the order the supplements were purchased. The Aug 18 BPC-157 product switch (Apeiron → ProHealth) doesn't change this chain — the repair role at Layer 1 is unchanged.
7. Phase 4 Synergy (Feed → Restore → Bridge)
Sunfiber → feeds F. prausnitzii's preferred substrate directly → Tri-Butyrin Supreme → supplies the butyrate F. prausnitzii would normally produce, bridging the gap while the species repopulates → Akkermansia 500 PRO → direct strain repletion for the other confirmed-missing species → MegaPre → broad-spectrum multi-fiber support feeding both keystone targets plus Bifidobacterium simultaneously. This is the most mechanistically dense chain in the protocol — four supplements, four distinct roles, one confirmed lab finding.
8. Energy Production Synergy — updated Aug 16, 2026
🆕 Mitopure clears damaged mitochondria via mitophagy → PQQ signals biogenesis of new mitochondria to replace them → CoQ10 supplies the electron-transport substrate each new mitochondrion needs to produce ATP → Creatine recycles that ATP rapidly under load, independent of mitochondrial throughput. This is now a genuine four-node chain rather than the two-node CoQ10/PQQ pairing it was before Aug 16 — clearance, construction, output, and recycling, in the order the cell actually needs them.
⚠️ Critical Pairing — D3 + K2
Vitamin D3 → increases intestinal calcium absorption → Vitamin K2 (MK-7) → activates the proteins (matrix Gla-protein, osteocalcin) that direct that calcium into bone rather than arterial walls. This is not treated as an optional stack in this protocol — D3 without K2, given the existing cardiovascular risk profile, is considered an incomplete and potentially counterproductive intervention.
9. Zinc / Magnesium Separation
Zinc Bisglycinate → taken with the 11 AM meal, separated 2+ hours from Magnesium Glycinate's 9 PM dose. Zinc and magnesium compete for the same divalent-cation intestinal transporters, so co-dosing them at high doses can blunt absorption of both — the existing schedule already separates them by roughly 10 hours, so no timing change was needed to accommodate the new addition.
🧩 Redundancy & Gap Analysis
Intentional Redundancy
Lipid Management — 4 pathways
Red Yeast Rice, Berberine, Super EPA Pro, and FiberMend each lower lipids through a mechanistically distinct route (synthesis inhibition, AMPK activation, VLDL suppression, bile-acid binding). This isn't 4x redundancy — it's coverage of 4 separate failure points, which is why LDL/ApoB moved as far as they did.
Methylation Support — 2 layers
Methyl-Guard Plus (targeted, higher-dose) and Basic Nutrients 2/Day (broad-spectrum, lower-dose) overlap deliberately — the multivitamin is the floor, Methyl-Guard is the targeted correction for two confirmed variants.
B12 Delivery — 3 sources
Methyl-Guard Plus, Basic Nutrients, and (minor/tertiary) Seed DS-01's endogenous-synthesis support all contribute methylcobalamin, addressing the MTRR-driven recycling shortfall from multiple angles rather than one large dose from a single source.
GABA-ergic Calming — 4 vectors
L-Theanine, GABA, and Ashwagandha within NeuroCalm, plus Magnesium Glycinate's independent NMDA-receptor-modulation route, hit the calming/catecholamine-buffering need from four distinct angles rather than maxing out one.
Identified Gaps
Gap 1 — Glutathione / NAC Medium Priority
No direct glutathione precursor (NAC or liposomal glutathione) is currently in the stack. Given the APOE e4 allele and the general oxidative-stress load of an active training regimen, this is a reasonable addition to evaluate — not urgent, since diet (cruciferous vegetables, adequate protein for endogenous synthesis) is already covering baseline need reasonably well.
Gap 2 — NAD+ / NMN Pathway Medium-Low Priority
NAD+ decline with age is a separate axis from the mitochondrial biogenesis/mitophagy/ETC-substrate/recycling stack already addressed above — Mitopure, PQQ, CoQ10, and creatine all leave NAD+ levels themselves untouched. This is flagged as a lower-priority frontier item worth researching further (see also the Longevity Frontier Review already on file) rather than an active gap being acted on now.
Gap 3 — Triglyceride / NMR Particle Cluster Resolved Sep 14, 2026 (TG) — NMR recheck still open
The Jul 27 NMR LipoProfile showed triglycerides at 144–153 (from a baseline of 85), LDL-P at 1453, small LDL particles at 298, and depleted large HDL — a pattern that, taken at face value, would look like new metabolic deterioration. Four points argued this was substantially a berberine-washout artifact rather than a genuine new problem:
1. Both draws (Jul 20 and Jul 27) fell inside berberine's scheduled 2-week OFF cycle (Jul 14–27) — day 7 and day 14 of the washout, respectively.
2. Berberine's AMPK-activation mechanism suppresses hepatic lipogenesis; withdrawing it predictably raises VLDL/TG output, and TG rose across the two draws exactly as that mechanism predicts (144→153).
3. LDL-C was simultaneously at a best-ever 103–108 across the same window — inconsistent with a genuine global lipid-metabolism deterioration, and more consistent with red yeast rice/EPA/FiberMend continuing to carry LDL independently while TG (whose only dedicated lever is EPA) absorbed the berberine withdrawal.
4. The pattern (isolated TG/small-particle rise with LDL-C stable-to-improving) matched what would be predicted from berberine washout specifically, rather than a broad metabolic-syndrome-style pattern that would also show rising glucose/insulin/A1c — which did not happen; those remained at best-ever levels through the same window.
✅ Confirmed Sep 14, 2026. A WellSpan lipid panel drawn ~7 weeks into the on-cycle berberine period (resumed Jul 28, 2026) put Triglycerides at 66 mg/dL — a series low, below both the 85 mg/dL Mar 2026 baseline and the 71 mg/dL Dec 2025 prior low. This is the confirmatory result the gating action called for: the berberine-washout hypothesis was correct, and the triglyceride-level concern is now resolved rather than merely hypothesized.
What remains open: the Sep 14 draw was a standard lipid panel, not an NMR LipoProfile — the small-LDL-particle count (298) and large-HDL depletion from Jul 27 were not re-measured. Those findings tracked mechanistically with elevated TG (via CETP-mediated lipid exchange), so a TG return to series-low levels is a strong signal the particle picture has also normalized, but that remains an inference rather than a direct re-measurement. A full NMR LipoProfile recheck is a separate, lower-urgency open item — worth doing at the next comprehensive panel, not urgent enough to gate any other decision the way the TG retest did.
1. Both draws (Jul 20 and Jul 27) fell inside berberine's scheduled 2-week OFF cycle (Jul 14–27) — day 7 and day 14 of the washout, respectively.
2. Berberine's AMPK-activation mechanism suppresses hepatic lipogenesis; withdrawing it predictably raises VLDL/TG output, and TG rose across the two draws exactly as that mechanism predicts (144→153).
3. LDL-C was simultaneously at a best-ever 103–108 across the same window — inconsistent with a genuine global lipid-metabolism deterioration, and more consistent with red yeast rice/EPA/FiberMend continuing to carry LDL independently while TG (whose only dedicated lever is EPA) absorbed the berberine withdrawal.
4. The pattern (isolated TG/small-particle rise with LDL-C stable-to-improving) matched what would be predicted from berberine washout specifically, rather than a broad metabolic-syndrome-style pattern that would also show rising glucose/insulin/A1c — which did not happen; those remained at best-ever levels through the same window.
✅ Confirmed Sep 14, 2026. A WellSpan lipid panel drawn ~7 weeks into the on-cycle berberine period (resumed Jul 28, 2026) put Triglycerides at 66 mg/dL — a series low, below both the 85 mg/dL Mar 2026 baseline and the 71 mg/dL Dec 2025 prior low. This is the confirmatory result the gating action called for: the berberine-washout hypothesis was correct, and the triglyceride-level concern is now resolved rather than merely hypothesized.
What remains open: the Sep 14 draw was a standard lipid panel, not an NMR LipoProfile — the small-LDL-particle count (298) and large-HDL depletion from Jul 27 were not re-measured. Those findings tracked mechanistically with elevated TG (via CETP-mediated lipid exchange), so a TG return to series-low levels is a strong signal the particle picture has also normalized, but that remains an inference rather than a direct re-measurement. A full NMR LipoProfile recheck is a separate, lower-urgency open item — worth doing at the next comprehensive panel, not urgent enough to gate any other decision the way the TG retest did.
Gap 4 — Zinc Repletion → Thyroid Cofactor Addressed Sep 14, 2026
Zinc was in-range but on a slow multi-draw downtrend (74→72→69→70→63 mcg/dL) — not an out-of-range flag, and the framing mattered, since a declining-but-normal trend calls for monitoring and modest reinforcement, not urgent correction. Zinc is a required cofactor for T4→T3 conversion, and this trend was being watched partly for that reason. Standalone Thorne Zinc Bisglycinate 15mg (1 cap/day, ordered Sep 10, started Sep 14, 2026) now closes this gap (see Immune, Hormonal & Structural above); copper status continues to be monitored alongside it given the known risk of copper depletion on long zinc-repletion courses.
Watch Items
DHEA-S / HPA-Axis Drift
Corrected Aug 14, 2026: in-range but trending downward across recent draws — being watched as a slow HPA-axis/adrenal-load signal rather than treated as a flag. No new supplement added for this; sleep, stress load, and training recovery are the levers being watched here before any nutritional intervention is considered.
Transient ANA Positive
A single positive ANA at low titer (1:40) self-resolved on retest. Low-titer transient ANA positives are common and frequently non-specific. No action taken, and none is currently indicated — flagged here for the longitudinal record only.
NMR Particle Recheck
Now the only open thread of the former Gap 3. With triglycerides confirmed back to a series low (66 mg/dL, Sep 14, 2026), a full NMR LipoProfile at the next comprehensive panel would directly confirm LDL-P, small LDL, and large HDL have normalized alongside TG rather than relying on the CETP-mechanism inference above. Not gating any current decision.
Closed Gaps
✅ Uric Acid Management
Resolved at 5.7, comfortably in range. No standalone uric-acid-targeted supplement needed or added.
✅ Ferritin / Iron Trend
Stabilized at 75. Corrected Aug 14, 2026: the Jan 2025 MCHC value of 31.6 is in-range, not a flag — it had been misread as a concern in an earlier pass. No iron supplementation needed or added.
✅ Keystone Microbiome Species
Phase 4's 4-supplement addition directly addresses the Jun 2026 GI-MAP finding. Marked closed at the intervention level; biological verification is still pending the 6-month GI-MAP retest.
✅ Zinc Repletion → Thyroid Cofactor
Standalone Thorne Zinc Bisglycinate 15mg (1 cap/day) started Sep 14, 2026, closing Gap 4. Copper status will be monitored on the next panel.
✅ Triglyceride / Berberine-Washout Hypothesis
On-cycle retest Sep 14, 2026 confirmed the Jul 2026 TG spike (144–153) was a washout artifact — Triglycerides came back at 66 mg/dL, a series low. The separate NMR particle recheck remains an open watch item (see above), but the TG-level concern itself is closed.
✅ Berberine Product/Dose Record
Corrected Sep 16, 2026: the stack uses Thorne Berberine, 200mg/capsule, 2 caps/day (400mg/day) — previously mis-recorded as "Thorne Berberine-500" at an implied 1000mg/day. No change in what's actually being taken; the correction is to the record only, and every mechanism and cross-reference above reflects the corrected product/dose.
👁️ Watch: Fiber Product Overlap
FiberMend and Sunfiber are both PHGG (partially hydrolyzed guar gum) sources, combining to roughly 12g/day of the same fiber type. This was reviewed deliberately and the decision was to continue both — they're dosed at different times for different primary purposes (FiberMend for bile-acid binding/lipid support, Sunfiber for F. prausnitzii substrate feeding) and the combined dose is still within a well-tolerated range. MegaPre is a distinct multi-fiber blend and is explicitly not part of this overlap.
No Harmful Redundancy Detected. Every case of overlapping mechanism in this stack (lipids, methylation, B12, calming, fiber) was reviewed and found to be either mechanistically distinct enough to justify, or an intentional belt-and-suspenders layer around a confirmed genetic or lab finding — not accidental duplication.
Mitopure — no redundancy, no gap closed. Mitopure's mitophagy mechanism is mechanistically distinct from both existing mitochondrial supplements (CoQ10's ETC substrate role, PQQ's biogenesis signal) and doesn't overlap with either. It also doesn't close Gap 1 (glutathione) or Gap 2 (NAD+/NMN) above — those remain open, separate frontier items unaffected by this addition. The Aug 18 BPC-157 product switch is likewise not a gap-closing event — it's a like-for-like product substitution within the existing Gut Architecture layer, not a new mechanism or a response to a newly identified gap. The Sep 14 Zinc Bisglycinate addition closed Gap 4, and the Sep 14 WellSpan retest closed the triglyceride half of Gap 3 — both are cases where a specific action directly resolved an identified finding, distinct from Mitopure and the BPC-157 switch above. The Sep 16 berberine product/dose correction is likewise not a gap-closing or protocol-changing event — it corrects the record to match what was actually being taken all along, with no mechanistic or dosing consequence.
📋 Action Plan — September 2026
| # | Action | Status | Rationale |
|---|---|---|---|
| 1 | NMR LipoProfile recheck at next comprehensive panel | Open — not gating | Confirms the small-LDL-particle and large-HDL findings from Jul 27 normalized alongside triglycerides, rather than relying on the CETP-mechanism inference. Lower urgency now that the TG-level concern (the former gating question) is resolved. |
| 2 | Standalone Zinc Bisglycinate 15mg addition | Enacted Sep 14, 2026 | Thorne Zinc Bisglycinate 15mg, 1 cap/day with the 11 AM meal — addresses the slow in-range zinc downtrend and its thyroid-cofactor role (Gap 4), separate from the trace amount already in Basic Nutrients 2/Day. |
| 3 | On-cycle triglyceride retest | Completed Sep 14, 2026 — TG 66, series low | Confirms the berberine-washout hypothesis for Gap 3. No further lipid-targeted supplement addition is warranted on the strength of the Jul 2026 spike. |
| 4 | Dietary investigation into TG/particle rise | Closed — not needed | The Sep 14 retest confirmed the rise was a berberine-washout artifact rather than a dietary shift, so no separate dietary audit is warranted. |
| 5 | BPC-157 product switch: Apeiron → ProHealth Longevity | Enacted Aug 18, 2026 | Straight product substitution, same mechanism and cycling schedule. No lab or genetic finding drove this change; see supplement-grading-report.html for the full brand-quality comparison. |
| 6 | Copper + ceruloplasmin monitoring alongside standalone zinc | Ongoing — next panel | Sustained zinc repletion without copper monitoring carries a known risk of secondary copper deficiency; add copper/ceruloplasmin to the next full panel. |
| 7 | Berberine product/dose record correction: "Berberine-500" → Thorne Berberine 200mg × 2 caps/day | Enacted Sep 16, 2026 | Record-only correction — the master supplement registry and every downstream report now reflect the actual product (Thorne Berberine 200mg/cap, formerly sold as Berbercap) and actual daily dose (400mg/day). No change to what's being taken or to any mechanism described in this report. |
| 8 | Coronary Artery Calcium Score (Agatston) added to record | Logged Aug 22, 2026 · added to this report Sep 16, 2026 | Score of 10 ("minimal" band) — first direct structural measurement of arterial plaque burden, corroborating the biomarker-level progress above. Single baseline scan; next natural recheck is 3–5 years out, not the next quarterly panel. |
Explicitly NOT doing: no uric acid supplement (already resolved), no iron supplementation (ferritin stable, no deficiency signal), no DHEA supplementation (watching the trend, not treating it), no iodine supplementation (not indicated by current thyroid-adjacent markers), no thyroid pharmaceutical of any kind, no curcumin/anti-inflammatory replacement for the CurcuPrime lost in the BPC-157 switch (noted, not acted on), no escalation of the Super EPA Pro dose beyond 3 caps/day, no zinc dose beyond the 1 cap/day (15mg) label dose, no new lipid-targeted supplement in response to the confirmed-resolved TG spike, no berberine dose change as part of the Sep 16 product/dose correction (the correction is to the record, not the regimen), no rescoring the CAC before the natural 3–5 year window, and no removals from the current stack — every existing supplement still has an active rationale.
🏗️ Protocol Architecture Summary
System coverage. 23 supplements now map across all 7 body systems (the Oct 1, 2026 BodyHealth Electrolytes addition is a second primary supplement in Immune, Hormonal & Structural, alongside LMNT — they alternate days rather than overlap), with Gut Architecture (7 primary + 2 supporting) and Cardiovascular (4 primary + 3 supporting) the most heavily resourced — appropriately, since those carry the two most active, lab-confirmed findings in the protocol right now. Mitochondrial & Cellular Energy moved from 2 to 3 primary supplements with the Aug 16 Mitopure addition, the smallest system by supplement count but now internally more complete (clearance, construction, output, and recycling all represented). The Sep 14, 2026 Zinc Bisglycinate addition and the Aug 18 BPC-157 product switch (Apeiron → ProHealth Longevity) don't change this system-coverage picture — zinc slots into Immune, Hormonal & Structural's existing role, and the BPC-157 switch is a like-for-like substitution within Gut Architecture's existing Layer 1 role.
Genetic alignment. Every supplement, including Mitopure, the new Pure BPC-157, and the new Zinc Bisglycinate, checks out as neutral-or-better against all four genetic findings (COMT, MTHFR, MTRR, APOE) — 22/22 compatible, with zero identified conflicts.
Synergy density. Nine distinct multi-supplement synergy chains are now active across the protocol, plus one non-negotiable critical pairing (D3+K2). The Aug 16 addition converted the two-node Energy Production pairing into a four-node chain — the single largest synergy-architecture change prior to this revision. The Sep 14 Zinc addition contributes a smaller, timing-focused synergy note (Zinc/Magnesium separation) rather than a new mechanistic chain. The Gut Ecosystem chain (#6) is unaffected by the Aug 18 BPC-157 switch since the repair role it plays is unchanged.
Redundancy profile. Four cases of intentional, reviewed overlap (lipids, methylation, B12, GABA-ergic calming), all serving distinct purposes rather than accidental duplication, plus one explicitly reviewed and retained fiber overlap (FiberMend/Sunfiber). No harmful redundancy identified anywhere in the stack.
Identified gaps — revised Sep 14, 2026. Two low/medium-priority frontier items remain open (glutathione/NAC, NAD+/NMN pathway) — worth continued research, not urgent action. The former highest-priority item — the TG/NMR particle cluster — is now substantially resolved: the Sep 14, 2026 on-cycle retest confirmed the berberine-washout hypothesis (TG 66, series low), closing the triglyceride-level concern; only a lower-urgency NMR particle recheck remains open as a watch item, not a gate. Gap 4 (zinc/thyroid cofactor) closed with the Sep 14 Zinc Bisglycinate addition. Five gaps are now closed (uric acid, ferritin/iron, zinc/thyroid cofactor, the triglyceride/berberine-washout question, and — pending 6-month verification — the keystone microbiome species). Two items are being watched without current action (DHEA-S/HPA-axis drift, transient ANA). The CurcuPrime curcumin co-formulation lost in the BPC-157 switch is noted, not treated as a new gap requiring its own replacement.
Bottom line — Sep 16, 2026. This remains, overwhelmingly, a reactive-and-corrective protocol — every existing supplement traces back to a specific lab finding, a specific genetic variant, or a specific gap identified through that process. The Sep 14 lab draw closes the loop on the protocol's longest-running open hypothesis: the Jul 2026 triglyceride spike was correctly diagnosed as a berberine-washout artifact, not a new metabolic problem, and no new lipid supplement was added chasing a false signal — this is the protocol's evidence-discipline working as intended, in both directions (act on confirmed findings, don't overreact to unconfirmed ones). The new Zinc Bisglycinate addition is a second, parallel example of that same pattern: a slow-moving, in-range trend was flagged (Gap 4), watched across five draws, and addressed once judged durable. The Sep 16 berberine product/dose correction is a third, smaller-scale example of the same evidence discipline applied to the protocol's own records: the actual product and dose in use (Thorne Berberine 200mg × 2 caps/day = 400mg/day) had been mis-recorded as "Berberine-500," and the fix touches the record only — nothing about what's being taken, or why, has changed. Also folded into this revision: the first direct structural cardiac imaging data point (CAC Agatston score, 10, "minimal" band, Aug 22, 2026) — a single baseline scan that corroborates rather than changes the cardiovascular story, with no trend to report yet and no rescoring due for 3–5 years. Mitopure remains the one genuine exception in this stack's history: a proactive, trial-evidence-driven addition made without a corresponding lab flag. The Aug 18 BPC-157 switch (Apeiron → ProHealth Longevity) was a sourcing/brand decision, not a therapeutic one. The one genuinely open item across all of this is the NMR particle recheck — low urgency, not gating anything, and the next comprehensive panel is the natural place to close it.
Genetic alignment. Every supplement, including Mitopure, the new Pure BPC-157, and the new Zinc Bisglycinate, checks out as neutral-or-better against all four genetic findings (COMT, MTHFR, MTRR, APOE) — 22/22 compatible, with zero identified conflicts.
Synergy density. Nine distinct multi-supplement synergy chains are now active across the protocol, plus one non-negotiable critical pairing (D3+K2). The Aug 16 addition converted the two-node Energy Production pairing into a four-node chain — the single largest synergy-architecture change prior to this revision. The Sep 14 Zinc addition contributes a smaller, timing-focused synergy note (Zinc/Magnesium separation) rather than a new mechanistic chain. The Gut Ecosystem chain (#6) is unaffected by the Aug 18 BPC-157 switch since the repair role it plays is unchanged.
Redundancy profile. Four cases of intentional, reviewed overlap (lipids, methylation, B12, GABA-ergic calming), all serving distinct purposes rather than accidental duplication, plus one explicitly reviewed and retained fiber overlap (FiberMend/Sunfiber). No harmful redundancy identified anywhere in the stack.
Identified gaps — revised Sep 14, 2026. Two low/medium-priority frontier items remain open (glutathione/NAC, NAD+/NMN pathway) — worth continued research, not urgent action. The former highest-priority item — the TG/NMR particle cluster — is now substantially resolved: the Sep 14, 2026 on-cycle retest confirmed the berberine-washout hypothesis (TG 66, series low), closing the triglyceride-level concern; only a lower-urgency NMR particle recheck remains open as a watch item, not a gate. Gap 4 (zinc/thyroid cofactor) closed with the Sep 14 Zinc Bisglycinate addition. Five gaps are now closed (uric acid, ferritin/iron, zinc/thyroid cofactor, the triglyceride/berberine-washout question, and — pending 6-month verification — the keystone microbiome species). Two items are being watched without current action (DHEA-S/HPA-axis drift, transient ANA). The CurcuPrime curcumin co-formulation lost in the BPC-157 switch is noted, not treated as a new gap requiring its own replacement.
Bottom line — Sep 16, 2026. This remains, overwhelmingly, a reactive-and-corrective protocol — every existing supplement traces back to a specific lab finding, a specific genetic variant, or a specific gap identified through that process. The Sep 14 lab draw closes the loop on the protocol's longest-running open hypothesis: the Jul 2026 triglyceride spike was correctly diagnosed as a berberine-washout artifact, not a new metabolic problem, and no new lipid supplement was added chasing a false signal — this is the protocol's evidence-discipline working as intended, in both directions (act on confirmed findings, don't overreact to unconfirmed ones). The new Zinc Bisglycinate addition is a second, parallel example of that same pattern: a slow-moving, in-range trend was flagged (Gap 4), watched across five draws, and addressed once judged durable. The Sep 16 berberine product/dose correction is a third, smaller-scale example of the same evidence discipline applied to the protocol's own records: the actual product and dose in use (Thorne Berberine 200mg × 2 caps/day = 400mg/day) had been mis-recorded as "Berberine-500," and the fix touches the record only — nothing about what's being taken, or why, has changed. Also folded into this revision: the first direct structural cardiac imaging data point (CAC Agatston score, 10, "minimal" band, Aug 22, 2026) — a single baseline scan that corroborates rather than changes the cardiovascular story, with no trend to report yet and no rescoring due for 3–5 years. Mitopure remains the one genuine exception in this stack's history: a proactive, trial-evidence-driven addition made without a corresponding lab flag. The Aug 18 BPC-157 switch (Apeiron → ProHealth Longevity) was a sourcing/brand decision, not a therapeutic one. The one genuinely open item across all of this is the NMR particle recheck — low urgency, not gating anything, and the next comprehensive panel is the natural place to close it.